Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tari Ann King, M.D.

Co-Author

This page shows the publications co-authored by Tari King and Anna Weiss.
Connection Strength

7.157
  1. ASO Author Reflections: Is It Necessary to Routinely Clip and Localize the Biopsy-Proven Malignant Lymph Node? Ann Surg Oncol. 2022 Mar 25.
    View in: PubMed
    Score: 0.994
  2. ASO Visual Abstract: How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective Consecutive Patient Cohort Study. Ann Surg Oncol. 2022 Mar 15.
    View in: PubMed
    Score: 0.992
  3. How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective, Consecutive, Patient Cohort Study. Ann Surg Oncol. 2022 Jan 18.
    View in: PubMed
    Score: 0.982
  4. Strategies to Optimize Axillary Surgery in Patients With Breast Cancer Receiving Neoadjuvant Endocrine Therapy. Oncology (Williston Park). 2020 Oct 09; 34(10):397-404.
    View in: PubMed
    Score: 0.899
  5. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach. Ann Surg Oncol. 2019 Dec; 26(13):4326-4336.
    View in: PubMed
    Score: 0.836
  6. Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk. Breast Cancer Res Treat. 2019 May; 175(1):229-237.
    View in: PubMed
    Score: 0.798
  7. Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. Ann Surg Oncol. 2021 Mar; 28(3):1358-1367.
    View in: PubMed
    Score: 0.223
  8. Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. NPJ Breast Cancer. 2020 Aug 13; 6(1):35.
    View in: PubMed
    Score: 0.222
  9. Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. NPJ Breast Cancer. 2020; 6:35.
    View in: PubMed
    Score: 0.222
  10. The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer. Ann Surg Oncol. 2020 Sep; 27(9):3393-3401.
    View in: PubMed
    Score: 0.220
  11. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol. 2019 Oct; 26(11):3502-3509.
    View in: PubMed
    Score: 0.205
  12. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Ann Surg Oncol. 2019 Nov; 26(12):3846-3855.
    View in: PubMed
    Score: 0.205
  13. Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence. Surg Clin North Am. 2018 Aug; 98(4):687-702.
    View in: PubMed
    Score: 0.190
  14. Neoadjuvant Endocrine Therapy in Clinical Practice: A Review. JAMA Oncol. 2021 11 01; 7(11):1700-1708.
    View in: PubMed
    Score: 0.060
  15. Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer. J Am Coll Surg. 2020 10; 231(4):434-447.e2.
    View in: PubMed
    Score: 0.055
  16. Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis. Ann Surg Oncol. 2019 Oct; 26(11):3517-3525.
    View in: PubMed
    Score: 0.052
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.